Fixed drug eruption after the Sinopharm COVID‐19 vaccine

Abstract

Abstract After coronavirus disease 2019 (COVID‐19) became widespread around the world, several vaccines have been developed with variable efficacy and potency and based on different platforms to control the pandemic. One of these vaccines is Sinopharm (BBIBP‐CorV), which is an inactivated virus that was released by Sinopharm's Beijing institute in the summer of 2020. The most commonly reported side effects of the Sinopharm vaccine have included pain at the injection site, muscle pain, headache and fatigue. Dermatological reactions are also reported as less common and were mainly local injection site reactions. Fixed drug eruption (FDE) is a rare and unusual adverse effect and accounts for less than 1% of all severe acute respiratory syndrome coronavirus 2 vaccine‐related cutaneous manifestations. FDE has not been reported following the COVID‐19 inactivated vaccine. Here, we describe a rare case of FDE following the administration of the first shot of the Sinopharm vaccine.

Keywords

• BBIBP‐Cor
• COVID‐19 vaccine
• fixed drug eruption
• side effects
• Sinopharm